MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations

MEDITE Cancer Diagnostics specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announced the restructuring of its organization in Germany to position the Company for revenue growth and profitability.

Effective immediately, three new reporting lines have been established for the organization in Germany. All sales, marketing and sales fulfillment personnel and activities will report into Jeff Rencher, Chief Marketing and Business Development Officer. All manufacturing, R&D, technical service and quality management personnel and activities will report into Stephen Von Rump, Chief Commercialization and Strategy Officer. All financial personnel and activities will report into Susan Weisman, Chief Financial Officer. Mr. Rencher, Mr. Von Rump and Ms. Weisman all report directly to David Patterson, Chief Executive Officer of the Company.

“The purpose of this reorganization is to position the Company for the next level of growth and profitability,” said Mr. Patterson. “To reach our goals of globalization and revenue increase requires a different approach to the business. We needed to integrate the organization and put in place the infrastructure needed to achieve those goals.”

Near-term objectives for the new organization include refocusing sales activities to better serve the existing customer base, pursue new sales opportunities, and revamping manufacturing, service and R&D activities to improve quality and customer support, and better align the company’s product portfolio to new global opportunities.